The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of MedicineThree presentations at the ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Investing.com - TD Cowen initiated coverage on Akero Therapeutics (NASDAQ: AKRO) with a Buy rating and a $76.00 price target on Monday. The company, currently valued at $3.91 billion, has seen its ...

Akero Therapeutics Inc. company and executive profile by Barron's. View the latest 1AKRO company infomation and executive bios.

Pegozafermin, ETNB's FGF21 analog, shows promise in late-stage trials for MASH & severe hypertriglyceridemia. Key data & ...

Akero Therapeutics Inc. (NASDAQ:AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced that its amyloidosis treatment, called anselamimab, failed to meet its ...